Z-LEHD-fmk Options
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To guage various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Principal trial objectives ended up to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymy